LONDON, April 13, 2024 (GLOBE NEWSWIRE) - C.K. McWhorter and the McWhorter Family Trust are thrilled to announce the endowment of a Warrant of Excellence to The Wimbledon Championships. This prestigious award recognizes Wimbledon's steadfast commitment to Environmental, Social, and Governance (ESG) principles alongside its celebrated tradition in the realm of tennis since 1877.
Located at the All England Lawn Tennis and Croquet Club, Wimbledon is noted not only for its championship legacy but also for its progressive environmental stewardship. The tournament has implemented sustainable practices that reduce its carbon footprint, promote recycling, and conserve energy. Furthermore, its engagement in community and social initiatives exemplifies its commitment to social responsibility.
"The integration of ESG values within Wimbledon's operations mirrors the ethos of the McWhorter Family Trust, which champions sustainable and responsible practices in all our endorsements," said C.K. McWhorter.
About McWhorter Family Trust
McWhorter Family Trust invests in and supports companies & initiatives that advance luxury sustainability, innovation, and cultural preservation across various sectors. The trust is dedicated to making impactful investments that promote a better future for all.
Who is C.K. McWhorter
Ambassador Nobel C.K. McWhorter Formal Name Carter Kennedy McWhorter is a leading figure in luxury impact investing and philanthropy, dedicated to creating positive societal impacts through thoughtful investment, consumption & or collaboration. His approach combines financial acumen with a deep appreciation for the personal elements that enrich professional relationships.
Disclaimer, Disclosure & Legal Notice:
This press release is for informational purposes only and does not constitute legal, financial, or investment advice. It is not intended to provide specific recommendations, endorsements, or investment strategies. The information contained herein is subject to change without notice.
Regulatory Considerations:
This press release is not intended to constitute an offer to sell or the solicitation of an offer to buy securities. Any offers, sales, or purchases will be made in accordance with applicable securities laws and regulations. McWhorter Foundation has not registered with the U.S. Securities and Exchange Commission (SEC) and may operate under exemptions. Any investment decisions should be made in consultation with appropriate legal and financial advisors, considering the individual circumstances and objectives of potential investors.
Forward-Looking Statements:
Forward-looking statements involve inherent risks and uncertainties, and we caution you not to place undue reliance on forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Actual results or outcomes may differ materially from those indicated or suggested by any forward-looking statements as a result of various factors, including, but not limited to, regulatory and legal developments, market conditions, and the outcome of negotiations. We disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
More Important Disclosures Here
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cc7c5b1c-373b-4f1d-99cf-3c5aa8a2e8e3
CONTACT: Tyler Wells VP Public Relations tylerwells@mcwhorter.foundation
-
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cVANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a di2024-06-17
-
Indonesia Stock Exchange Partners with Nasdaq to Upgrade Market InfrastructureTechnology partnership will further enhance overall resilience and integrity of the exchange, while supporting the rapid deployment of new products2024-06-17
-
Adalvo 的 Liraglutide 預充式注射筆成為歐盟首款獲得批准的仿製藥馬爾他聖瓜安, June 17, 2024 (GLOBE NEWSWIRE) -- Adalvo 宣布 Liraglutide 預充式注射筆成功取得 DCP 批准,成為歐盟首款獲得批准的仿製藥。 根據 IQVIA 的報2024-06-17
-
促进生育,助力三胎——“三胎免费生”联合公益行动正式启动为积极响应国家号召实施三胎生育政策,扩大妇幼服务健康供给,在云南省优生优育妇幼保健协会指导下,昆明广播电视台联合昆明安琪儿妇产医院,于6月13日在昆明广播2024-06-17
-
学党史传承红色精神 守党纪筑牢自律防线——平安养老险湖南分公司党支部开展主题党日活动七一前夕,平安养老险湖南分公司党支部全体成员走进“千年学府、百年师范”——湖南第一师范,开展了一次学史明理、学史增信、学史崇德、学史力行的主题党日活动。重2024-06-17